Basic Information
VAXIGRIPTETRA SUSPENSION FOR INJECTION IN PREFILLED SYRINGE
INJECTION, SUSPENSION
Regulatory Information
SIN15477P
May 4, 2018
Prescription Only
Therapeutic
SUBCUTANEOUS, INTRAMUSCULAR
August 10, 2023
May 30, 2025
XJ07BB02
Company Information
SANOFI-AVENTIS SINGAPORE PTE. LTD.
SANOFI-AVENTIS SINGAPORE PTE. LTD.
Active Ingredients
Strength: 15 mcg/0.5 ml
Strength: 15 mcg/0.5 ml
Strength: 15 mcg/0.5 ml
Strength: 15 mcg/0.5 ml
Detailed Information
Contraindications
**4.3. Contraindications** Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), neomycin, formaldehyde and octoxinol-9. Vaccination should be postponed in case of moderate or severe febrile disease or acute disease.
Indication Information
**4.1. Therapeutic indications** VaxigripTetra is indicated for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine for: - active immunisation of adults, including pregnant women, and children from 6 months of age. The use of VaxigripTetra should be based on official recommendations.